

VU Research Portal

Analysis and biochemical characterization of degradation products of anti-Alzheimer's drugs

de Azevedo Marques, L.

2011

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

de Azevedo Marques, L. (2011). *Analysis and biochemical characterization of degradation products of anti-Alzheimer's drugs*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Chapter 5

Stability - indicating study of the anti-Alzheimer's drug galantamine hydrobromide

Adapted from:

Lygia Azevedo Marques, Ismail Maada, Frans J.J. de Kanter, Henk Lingeman, Hubertus Irth, Wilfried Niessen and Martin Giera. - *Stability - indicating study of the anti-Alzheimer's drug galantamine hydrobromide* Journal of Pharmaceutical and Biomedical Analysis - accepted

Abstract

Galantamine hydrobromide was subjected to different stress conditions (acidic, alkaline, thermic, photolytic and oxidative). Degradation was found to occur under acidic, photolytic and oxidative conditions, while the drug was stable under alkaline and elevated temperature conditions. A stability-indicating reversed-phase liquid chromatographic method was developed for the determination of the drug in the presence of its degradation products. The method was validated for linearity, precision, accuracy, specificity, selectivity and intermediate precision. Additionally, the degradation kinetics of the drug was assessed in relevant cases. The kinetics followed a first order behavior in the case of acidic and photolytic degradation, while a mixed kinetics behavior was found for the oxidative degradation. The degradation products were characterized by mass spectrometry and nuclear magnetic resonance spectroscopy. Dehydration, epimerization and *N*-oxidation were processes observed during the degradation of galantamine. Moreover, if sufficient material could be isolated the inhibitory activity against the target enzyme acetylcholinesterase was also assessed.

Introduction

Galantamine hydrobromide (**1**) is an acetylcholinesterase (AChE) inhibitor which is used to moderate and delay the manifestation of Alzheimer's disease (AD) symptoms. It is the AD drug most recently approved by the FDA (Hoffmann and Hock, 2004). **1** is a tertiary alkaloid, isolated from the bulbs and flowers of Caucasian snowdrop (*Galanthus woronowii*, Amaryllidaceae). The cost of obtaining galantamine from natural sources (Narcissus species) is very high (de Jong *et al.*, 2006). A total synthesis procedure via 2-narwedine has been extensively worked out for large-scale industrial production (Küenburg *et al.*, 1999). **1** was launched under the commercial name of Reminyl® which was changed in 2005 to Razadyne® (Berkov *et al.*, 2008b, Leonard *et al.*, 2005). **1** is also monographed by the European Pharmacopoeia and the United States Pharmacopoeia (European Pharmacopoeia 7th edition, 2010a, USP, 2008).

Although **1** is on the market for a couple of years, only a few studies about its stability have been described (Leonard *et al.*, 2005, Visky *et al.*, 2005), in spite of the fact that stability testing is an important topic in order to ensure the quality and the safety of drugs (Bakshi and Singh, 2002).

Up to now, accelerated stability studies for two salts of galantamine: galantamine lactate and galantamine hydrobromide (**1**) have been described. The stability so far was investigated using different pH values and different temperatures (Leonard *et al.*, 2005). A degradation study of **1** in Reminyl tablets also has been published. In this study, the main objective was to compare two different separation methodologies, namely: reversed-phase liquid chromatography with UV detection (RP-LC-UV) and capillary electrophoresis with tandem mass spectrometric detection (CE-MS/MS). The study was based on ICH guidelines, but only part of the mandatory stress conditions were investigated (Visky *et al.*, 2005).

In the here presented work, a fully validated stability assessment for **1** is presented, including degradation kinetics, structure elucidation of the degradation products, and bioactivity assessment against the target enzyme AChE. The degradation products were separated using a RP-LC-UV method and spectroscopic and spectrometric methods were used for structural elucidation. After subsequent semi-preparative isolation, particular degradation products were tested for their inhibitory effect against the target enzyme AChE.

5.2 Experimental

5.2.1 Materials

All solvents used were of HPLC grade. Methanol (MeOH) and acetonitrile (ACN) were purchased from Biosolve (Valkenswaard, the Netherlands), Milli-Q water was obtained from a Milli-Q purification system (Millipore, Amsterdam, The Netherlands). Ammonium acetate came from J.T. Baker B.V. (Deventer, The Netherlands). Galantamine hydrobromide (**1**) was supplied by Alexis (Lausen, Switzerland) and kindly supplied by Janssen-Cilag (Tilburg, The Netherlands). A stock solution of **1** (5 mM) was prepared in water and demonstrated to be stable for five months at 4°C. Hydrogen peroxide 30% came from Merck (Darmstadt, Germany). For bioactivity measurements, the acetylcholinesterase (AChE) (EC 3.1.1.7) type VI-S from *Electrophorus electricus* (electric eel) was obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 7-Acetoxy-1-methylquinolinium iodide (AMQI) was purchased from Fluka (Buchs, Switzerland). The enzyme and the substrate stock solutions were kept at -80°C until use. 96-well black, solid plates were from Brand (Wertheim, Germany). All other chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany).

5.2.2 Instrumentation

5.2.2.1 Analytical Liquid chromatography

RP-LC for analytical analysis was performed with a quaternary Agilent HPLC 1100 series pump (Agilent Technologies, Waldbronn, Germany), delivering a gradient of 10 mM ammonium acetate (pH 5.8) : MeOH at 200 μ L/min (solvent A: 10 mM ammonium acetate (pH 5.8) : MeOH (95:5 v/v) and solvent B: 10 mM ammonium acetate (pH 5.8) : MeOH (5:95 v/v). The gradient program was as follows: 0–5 min 0% B, followed by an increase to 90% B in 40 min, which was held for five minutes. The autosampler was a Gilson model 234 (Villiers Le Bel, France) with a 25 μ L injection loop. Separation was performed on a Waters SunFire C₁₈ (150 mm \times 2.1 mm, 3.5 μ m) (Waters, Milford, MA, USA) column used in combination with a Phenomenex C₁₈ (4 mm \times 2 mm, 5 μ m) precolumn cartridge (Aschaffenburg, Germany). The temperature was kept at 30 °C by a Spark column oven (Spark Holland, Emmen, The Netherlands). The column effluent was monitored by UV absorption using an Agilent 1100 series diode-array detector (DAD). Kinetic data were evaluated at a wavelength of 290 nm.

5.2.2.2 Semi-preparative liquid chromatography

Semi-preparative RP-LC analysis was performed with a binary HPLC system consisting of two Shimadzu LC-10Ai pumps (Shimadzu, 's Hertogenbosch, The Netherlands), delivering the same solvents as used for the analytical separation at a flow rate of 4 mL/min. The injection was done using a Valco manual injection valve (Amstelveen, The Netherlands), with a 250 μ L injection loop. The separation was performed on a Merck Purospher STAR RP-18e (250 mm

× 10 mm, 5 μm) (Darmstadt, Germany), including a precolumn of the same material (10 mm × 4 mm). The temperature was held at 30 °C by a Spark column oven. For the collection of the degradation products under acidic conditions, the same gradient was used as for the analytical separation. The applied gradient for the preparative separation of the degradation products formed under irradiation conditions was as follows: 0 to 40 min 0% B to 20 % B ramped to 80% B at 55 min. The column effluent was monitored both at 290 nm and 215 nm. All fractions were collected manually.

5.2.2.3 Light source

The Xenon Arc lamp used for the irradiation of **1** was from AEG (Nürnberg, Germany) and operated at 150 Watt.

5.2.2.4 Mass spectrometric analysis

For the MS analysis of oxidative degradation products in deuterated water, a model 6520 Q-TOF mass spectrometer (Agilent Technologies, Waldbronn, Germany) was used. Analyses were performed with electrospray ionization (ESI) in the positive ion mode with direct infusion at a flow rate of 5 μL/min. The following conditions were used: interface voltage 3.5 kV, nebulizer and desolvation gas (Nitrogen (99.9990%)) 15 psi and 4 L/min, respectively, source temperature 350 °C. Spectra were acquired in the range of m/z 50–500. MS/MS experiments were performed with an isolation width set to medium (~4 m/z -units wide) and a collision energy of 30 eV. Argon (99.9995%) was used as collision gas. High resolution measurements were acquired after tuning and instrument calibration according to the manufacturer's specifications.

Degradation products formed under irradiation and acidic conditions were analyzed using a Shimadzu IT-TOF instrument equipped with an ESI source operated in positive ion-mode. The curved desolvation line and the heating block were set to 200 °C, the interface voltage was set to 4.5 kV, while a voltage of 1.7 kV was applied for the detector. Nitrogen (99.9990%) was used as a nebulizing gas at a flow of 1.5 L/min and as drying gas at a flow of 10 L/min. For the fragmentation experiments, argon (99.9995%) was used as collision gas.

In the full spectrum mode, data was acquired from m/z 100–1000, with an ion accumulation time of 30 ms. MS² experiments were performed with an ion isolation time of 30 ms, an isolation width set to 3 m/z -units, and a frequency (q) of 45 kHz. Both collision energy and gas were set to 50%. MS³ parameters were the same as used for MS² measurements.

5.2.2.4 NMR analysis

All NMR measurements were performed on a Bruker Avance 500 (Fallanden, Switzerland), equipped with a cryoprobe, or a Bruker 400 (Fallanden, Switzerland); the residual methanol-d₄ signal was used as reference. ¹H NMR measurements were carried out at 500 or 400 MHz, while the ¹³C NMR experiments were performed at 100 or 125 MHz.

5.2.3 Protocols

5.2.3.1 Method Validation

Validation of the optimized RP-LC system was carried out according to ICH guidelines (ICH, 2005) with respect to the following parameters: linearity, precision, accuracy and specificity. Additionally, system suitability parameters were evaluated.

5.2.3.2 Application of the validated RPLC method for the determination of galantamine (1) in Reminyl retard capsules

The validated RPLC method was applied to quantify the amount of **1** in Reminyl retard capsules. An accurately weighted aliquot was taken in duplicate from a total sample of ten homogenized Reminyl capsules. The sample was diluted to an expected concentration of 1.7 mM with MeOH and submitted to ultrasonication for 30 min. The solution was filtered through a 0.45 μm filter and subsequently diluted with eluent A to a final expected concentration of 30 μM . This solution was analyzed in triplicate with the above described analytical RPLC system. From the results, the capsule content was determined.

5.2.4 Degradation and kinetics studies

A stock solution of **1** (5 mM) in water was prepared and stored at 4 °C until use. This stock solution was appropriately diluted for all degradation and kinetics experiments to reach a final test concentration of 200 μM . The degradation and kinetics of **1** were investigated under acidic, basic, oxidative and elevated temperature conditions as well as under irradiation with a Xenon Arc lamp at 150 W. Samples were placed in the autosampler tray just prior to their injection. If not stated otherwise, they were stored at 4 °C in a refrigerator until injection. For all conditions under which degradation was observed, kinetics were determined. Data was analyzed using the software Prism version 5.08 (Graph Pad, San Diego, CA, USA).

5.2.4.1 Acidic conditions

1 was treated with 1 M hydrochloric acid (HCl) at 80 °C. The starting concentration (c_0) was measured by preheating the solution of 1 M HCl to 80 °C and quickly removing an aliquot of 200 μL after the stock solution of **1** has been added. The aliquot (200 μL) was cooled to room temperature (RT) and 100 μL was taken and diluted with 210 μL of cold mobile phase A and 90 μL of 1 M NaOH for neutralization. This dilution resulted in a final concentration of 50 μM of **1** at time 0 min. From 0 to 20 min, an aliquot was drawn in the described manner every 5 min, from 20 until 120 min aliquots were collected in 10 min intervals. Finally, from 120 until 300 min, aliquots were collected in 30 min intervals.

5.2.4.2 Alkaline conditions

1 was heated to 80 °C in a 1 M solution of sodium hydroxide (NaOH). The same sampling procedure as described for the acidic conditions was applied, except that 1 M HCl was added after sampling instead of 1 M NaOH (in 5.2.4.1).

5.2.4.3 Oxidative conditions

1 was heated to 80 °C in 3% H₂O₂. The same sampling procedure as described for the acidic and alkaline conditions was applied, except that 300 µL of cold mobile A was added instead of 210 µL plus 90 µL 1 M NaOH. The final aliquot was taken at 240 min after starting the collection. As the oxidative degradation of **1** was a very rapid process, the storage stability at 4 °C was investigated and the samples proved to be stable under these conditions for at least 2 days. For this reason, samples could be stored in the fridge at 4 °C until injection.

5.2.4.4 Elevated temperatures

As control experiment for the above mentioned investigations, **1** was heated to 80 °C in water for 300 min as well as for 2 months inside a column oven. The same sampling procedure as described for the oxidative conditions was applied (addition of 300 µL of cold mobile A to the sample). For the long term stability testing, the sampling was performed at the following intervals: from the starting point until 7 days, one sample per day was taken. From day 7 until day 15, one sample was taken and from day 15 until day 60 samples were taken every 15 days. As a control, a solution of **1** wrapped in aluminum foil, stored at room temperature was treated in the same manner.

5.2.4.5 Irradiation

A solution of **1** in water was placed in a Duran® glass flask and irradiated with a Xenon Arc lamp at 150 W. Duran® glass has a “natural” cut off at 310 nm according to the manufacturer’s specifications. In order to exclude the possible effect of the heat that arises from the irradiation, a control sample in an aluminum foil covered flask was irradiated. The same sampling procedure as described for the oxidative conditions was applied (addition of 300 µL of cold mobile A to the sample with a final aliquot taken at 180 min after initialization).

5.2.5 Large scale preparation of degradation products

5.2.5.1 Degradation under acidic conditions

For the large scale generation of degradation products, two separate reaction batches of 6 mg of **1** in 10 mL of 1 M HCl were refluxed for 2 hours. The solutions were alkalinized with 3 mL of an aqueous sodium hydroxide solution (5 M) and extracted with three portions of 5 mL dichloromethane (DCM). The combined organic layers were washed carefully with 20 mL of water. The organic phase was dried over anhydrous magnesium sulfate, filtered and evapo-

rated to dryness under a gentle stream of nitrogen. The resulting residue was dissolved in 1 mL of mobile phase A and 250 μL portions were injected into the specified preparative LC system. The collected fractions were pooled and the DCM extraction was repeated, using three portions of 20 mL DCM. The solid residues were dried under vacuum, weighted and submitted to NMR analysis and/or bioaffinity testing.

5.2.5.2 Oxidative degradation products

For evaluation of the major degradation product under oxidative conditions, 2.5 mg of **1** was incubated in 3% H_2O_2 , which was prepared from 30% H_2O_2 solution by dilution with deuterium oxide (D_2O). The total volume of this solution was 5 mL. The solution was refluxed for 2 hours at 80 $^\circ\text{C}$. The resulting solution was diluted with D_2O and directly infused into a mass spectrometer, as described under 5.2.2.4.

5.2.5.3 Photolytic degradation products

For the generation of photolytic degradation products, three separate batches of 4 mg of **1** in 10 mL of water were irradiated under the above stated conditions. The liquid-liquid extraction and preparative isolation was applied as described under 5.2.5.1; in this case, addition of 200 μL of 5 M NaOH was used to alkalinize the solution. The solid residues were dried under vacuum, weighted and submitted to NMR analysis. Each collected fraction was additionally injected into the analytical LC system to control the purity.

5.2.6 Acetylcholinesterase (AChE) inhibition assay

The AChE activity was determined according to (Marques *et al.*, 2010a) with some modifications: 10 mM stock solutions in MeOH of the isolated degradation products, formed under acidic conditions, were prepared from the purified material and used for further dilutions. The AChE bioactivity assay was measured in a 96-well plate using AChE dissolved in 20 mM Tris-HCl buffer pH 7.5, 2 g/L PEG 6000 and 1 g/L ELISA blocking reagent. As substrate, AMQI 2 μM in 50 mM of citrate buffer at pH 5 was used. 8 μL of a solution containing the degradation products (10 mM, 0.2 mM) in MeOH were dried in the wells. First, 100 μL of the enzyme stock solution (0.1 U/mL) was added to all wells of the plate with a multichannel pipette. 100 μL of enzyme solution was added to the wells containing the test compounds (dried). This resulted in the stock solution of the analytes. From these wells, 100 μL was taken and subsequently diluted 1:1 into the other wells already containing 100 μL enzyme solution. The dilutions on the microtiterplate were performed on ice. After the plate was heated to RT, 100 μL of the substrate solution was added to all wells. The final concentrations for the enzyme and substrate were 0.05 U/mL and 1 μM , respectively. The fluorescence intensity was measured 30 seconds after substrate addition for 6 time points within 5 minutes using a Victor3 plate reader (PerkinElmer, Waltham, MA, USA) at 405 nm and 520 nm for excitation and emission. From this data, the slope of the enzymatic reaction was generated and plotted against the decimal logarithm

of the concentration of the substance added. As a positive control, the IC₅₀ of **1** using a stock solution of 10 mM was measured following the same procedure as described above. The IC₅₀ curves were generated with the software Prism version 5.08. (Graph Pad, San Diego, CA, USA).

5.3 Results and discussion

5.3.1 Validation of the RPLC method

The following system suitability parameters were found: capacity factor 6.5, theoretical plate number 41636 and a tailing factor of 1.3. The results are in accordance with the USP method for **1**, specifying a tailing factor not higher than 2.0 (USP, 2008). The response of **1** was linear (R^2 0.9990) in the working range between 2.5 and 60 μ M ($y = 25.63(\pm 0.10)x - 7.35(\pm 2.90)$). Repeatability and intermediate precision (%RSD) was less than 2%. A one-way ANOVA proved that there is no significant difference between days. Good accuracy with quantitative recoveries was achieved, indicating that the method enables accurate determination of the analytes (Table 5.1).

The accuracy in the case of the oxidative stress conditions could not be evaluated, due to the fast degradation of **1**. The irradiation and elevated temperature experiments were carried out in water, hence no matrix effects were to be expected. Specificity was assessed by applying the peak purity function of the Chemstation software to all samples under all stability testing conditions. The wavelength 290 nm was found to be more specific and therefore used for the determination of **1**.

5.3.1.1 Application of the validated RPLC method for determination of galantamine in Reminyl® retard capsules

The validated RPLC method was applied to the quantification of **1** in Reminyl® retard capsules. The mean recovery obtained was $100 \pm 1.5\%$ ($n = 6$). The obtained result is in accordance with the USP, which demands a content between 98 and 102%.

5.3.2 Degradation and kinetics studies

Degradation studies permit to know the quality of a drug under the influence of different conditions and the degradation kinetics permits to measure the speed of these processes. Such testing is important to verify the stability of the drug and to assess the possibility to form degradation products. **1** proved to be stable for at least 300 min at 80 °C under alkaline conditions and for at least 60 days under neutral conditions. However, when **1** was exposed to a strong light source, acidic conditions or oxidative conditions, degradation occurred. Table 5.2 gives an overview of the found degradation products classified according to the different stability conditions under which their formation occurred. Figure 5.1 shows the chromatograms at 215 nm of the separation of the degradation products under acidic, oxidative and photolytic conditions.

Table 5.1 Recovery studies (n= 3) performed under acidic and basic conditions.

Actual concentration (μM)	Calculated concentration (μM)	RSD (%)	Recovery (%)
Acid			
5.0	5.1	1.2	102.3
10.0	9.9	0.7	98.9
15.0	14.9	1.4	99.4
30.0	30.3	0.6	100.9
Base			
5.0	5.1	0.9	102.5
10.0	10.2	1.4	101.2
15.0	15.1	2.1	100.9
30.0	30.6	0.5	101.9

5.3.2.1 Acidic conditions

A solution of **1** was degraded at 80 °C in 1 M HCl. The semi-logarithmic plot of the concentration of **1** (μM) against time indicated an apparent first order degradation kinetics. The degradation rate constant (k) was calculated by the use of the equation $\ln c = \ln c_0 - kt$, where c_0 is the concentration of **1** at time $t = 0$ and c is the concentration at time t . This means that k is equal to the slope of the obtained plot. Under the described experimental conditions, the regression coefficient (R^2) for the logarithmic plot was determined to be 0.9909, while k was $0.2185 \pm 0.005242 \text{ h}^{-1}$. In acidic media at 80 °C after 300 min, one major and four minor compounds (below 1.7%) were formed. After 120 min under reflux, three major and two minor compounds were formed. The three major compounds (**2**, **3** and **4**) could be collected, two of which could be identified by NMR (see Table 5.2).

5.3.2.2 Oxidative conditions

A solution of **1** was treated at 80 °C with 3 % H_2O_2 . The semi-logarithmic plot of the concentration of **1** (μM) against time indicated an apparent two phase kinetics. The degradation rate




Figure 5.1 RPLC chromatograms (215 nm) of degradation studies performed under acidic, photolytic and oxidative conditions. Galantamine corresponds to peak **1** in the chromatogram, other peak numbers refer to Table 2.

constants (k) were: k fast: $5.162 \pm 0.6595 \text{ h}^{-1}$ and k slow: $0.7848 \pm 0.09513 \text{ h}^{-1}$ with 40.63 ± 3.99 % of fast decay. The regression coefficient (R^2) for the plot was determined to be 0.9992. A first hypothesis for this behavior was the degradation of H_2O_2 during time. To confirm this hypothesis, H_2O_2 was titrated with potassium permanganate (KMnO_4) in acidic media (European Pharmacopoeia 7th edition, 2010b). The concentrations found before and after heating were not significantly different, meaning that the observed kinetics is not related to the degradation of H_2O_2 over time. Hence, an explanation of the apparent two phase kinetic behavior cannot be given. The degradation at 80°C and after 2 h under reflux revealed the production of one major compound and numerous unidentifiable products at rather low amounts (<0.5 %). The major compound was identified as **5** by MS using the methodology described in section 5.2.5.2.

5.3.2.3 Photolytic conditions

A solution of **1** was irradiated with a Xenon Arc lamp. The semi-logarithmic plot of the concentration of **1** (μM) against the time indicated an apparent first order degradation behavior. Under the described experimental conditions, the regression coefficient (R^2) for the logarithmic plot was determined to be 0.9976, while k was $0.7453 \pm 0.01023 \text{ h}^{-1}$. A control sample covered with aluminum foil was submitted to the same conditions; the analysis revealed that no degradation occurred.

5.3.3 Structural elucidation of degradation products

5.3.3.1 Degradation under acidic conditions

After the initial detection of the degradation products under acidic conditions, the compounds were isolated for a complete structure elucidation as described in 5.2.5. The yield for compounds **2**, **3** and **4** (numbers according to Table 5.2) was 2.9, 1.8 and 1.7 mg, respectively. This material was used for all further spectroscopic analyses.

NMR data was conclusive to identify peak **2** as epigalantamine (Jegorov *et al.*, 2006) and peak **4** as 3-methoxy-11-methyl-9,10,11,12-tetrahydro-4aH-benzo[2,3] benzofuro[4,3-cd] azepine (Han *et al.*, 1992) referring to earlier published ¹H-NMR data. Both structures can be expected under acidic conditions as epimerization and dehydration are well known processes under such conditions (Zhang *et al.*, 1989). The recorded MS and MSⁿ data can be found in the supplementary material S1.

5.3.3.2 Oxidative degradation products






The chromatogram of **1** heated in a solution of 3% H₂O₂ showed one major degradation product, besides a huge number of minor degradation products. We focused on the extraction of the major component. Unfortunately, we were not able to extract the formed degradation product into a variety of organic solvents (e.g. DCM, ethyl acetate, ethyl acetate containing 0.05 M triethylamine (TEA) (0.7% v/v) and methyl-tert.-butyl ether).

As the isolation of the substance, which we supposed to be Galantamine *N*-oxide (**5**) (number according to Table 5.2) was unsuccessful, we applied the MS based identification strategy described in 5.2.5.2. Earlier studies dealing with the extraction of diphenhydramine *N*-oxide (Kumar *et al.*, 1998) reported about problems in liquid-liquid extraction procedures, which the authors related to the extreme hydrophilicity of *N*-oxides and adhesion to glassware. In the cited article, the recoveries were found to be satisfactory by extracting the diphenhydramine *N*-oxide with ethyl acetate containing 0.72% (v/v) of TEA. Unfortunately, in our case this solvent system did not allow the extraction of **5** either. Another study related to the phase I metabolism of **1** claimed the mass spectrometric identification of **5** (Malakova *et al.*, 2007). Controversially, the described method of the *N*-oxide formation was related to an article dealing with dimefluron (Císař *et al.*, 2005). Although our MS data was in very good agreement with the earlier published data (Malakova *et al.*, 2007) (the recorded MS and MSⁿ data can be found in the supporting information S1), the lack of additional NMR data, or other proof for the definitive identity of **5** encouraged us to seek for another strategy proving the *N*-oxides identity. The necessity of doing so was additionally based on the fact that, although the main reaction of H₂O₂ with amine-containing substances is the formation of *N*-oxides, H₂O₂ can also cause the hydroxylation at double bonds or aromatic systems (Marques *et al.*, 2010). In both cases, an *m/z* value of +16 would be found for the molecule, thereby rendering a solely MS based distinction between hydroxylation and *N*-oxide formation impossible. Therefore, we

Table 5.2 Summary of analytical data. All detected substances are shown together with their corresponding retention time (Rt), m/z of the protonated molecule, most likely molecular formula and UV maximum. $^1\text{H-NMR}$ references and structures are given in cases where substances were identified based on spectroscopic data including NMR. aerror given in parts

Number	Rt (min)	Test condition	m/z (error - ppm) ^a	Most likely molecular formula
1 base form	16.3	Parent compound	288.1593 (0.42)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
2	18.4	acidic	288.1593 (0.42)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
3	22.6	acidic	270.1487 (0.58)	$\text{C}_{17}\text{H}_{20}\text{NO}_2^+$
4	24.3	acidic	270.1480 (0.58)	$\text{C}_{17}\text{H}_{20}\text{NO}_2^\pm$
5	17.8	oxidative	304.1551 (-2.5)	$\text{C}_{17}\text{H}_{22}\text{NO}_4^+$
6	12.8	photolytic	306.1680 (6.5)	$\text{C}_{17}\text{H}_{24}\text{NO}_4^+$
7	14.3	photolytic	288.1573 (7.4)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
8	15.0	photolytic	306.1680 (6.5)	$\text{C}_{17}\text{H}_{24}\text{NO}_4^+$
9	17.5	photolytic	288.1572 (7.7)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
2	18.0	photolytic	288.1577 (5.9)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
10	19.0	photolytic	288.1577 (5.9)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$
11	26.3	photolytic	288.1571 (8.1)	$\text{C}_{17}\text{H}_{22}\text{NO}_3^+$

per million with respect to the calculated molecular formula, bUV spectra for all degradation products can be found in the supplementary material S2, csee supplementary material for comment about the published NMR data.

¹ H-NMR (Ref)	UV maxb (nm)	Structure
Lubbe <i>et al</i> , 2010	215	galantamine 
(Jegorov <i>et al</i> , 2006)	215	epigalantamine 
-	210	Not determined
(Han <i>et al</i> , 1992)c	210	3-methoxy-11-methyl-9, 10,11,12-tetrahydro-4aH- benzo[2,3] benzofuro [4,3-cd]azepine 
-	215	galantamine- N-oxide 
-	210	Not determined
-	210	Not determined
-	210	Not determined
(Lee <i>et al</i> , 1998)	210	3-methoxy-11-methyl-7,8,9,10, 11,12-hexahydro-4aH- benzo[2,3] benzofuro[4,3-cd] azepin-6(°H)-one 
(Jegorov <i>et al</i> , 2006)	215	epigalantamine
-	210	Not determined
-	210	Not determined

performed hydrogen/deuterium exchange experiments (Liu *et al.*, 2005). Hence, we diluted the solution of **1** after oxidative degradation with D₂O before infusion into the MS. Subsequently, the theoretical number of exchanged hydrogen atoms was compared to the found values. For **1** itself, an *m/z* increase of +2 is observed when comparing the spectra in the deuterated to the non deuterated solvent. This is due to hydrogen exchange of the hydroxyl hydrogen atom and protonation by D⁺ rather than H⁺. Relative to **1**, the oxidative degradation product, would show an *m/z* increase of +19 in the deuterated solvent if an additional hydroxyl function is introduced and an *m/z* increase of +18 in the case of an *N*-oxide. An *m/z* increase after the treatment of **1** with H₂O₂ of +18 was observed, thereby clearly indicating the formation of an *N*-oxide. This assumption could be further strengthened by the acquisition of MS/MS data (Figure 5.2), which clearly showed the formation of identical fragment after the cleavage of the azepin ring and a water loss of the molecules, when comparing **5** with **1**.

5.3.3.3 Photolytic degradation products

Due to the large number of formed products by photolytic degradation, the large scale preparation and isolation of these products was not feasible for all of them. The recorded MS and MSⁿ data can be found in the supplementary material S1. The three major compounds were isolated with the preparative RPLC system described above. For all three isolated substances, NMR measurements were carried out, as specified in Table 5.2 (Jegorov *et al.*, 2006, Lee *et al.*, 1998). Analytical RPLC-UV analysis revealed that the purity of the collected fractions was lower than 70%. This and the fact that the overall achieved recovery for each peak was less than 10% (with respect to the total amount of **1**), rendered a full structural elucidation impossible. A better chromatographic separation of the substances in the preparative system could unfortunately also not be achieved by exchanging MeOH against ACN in the eluents. Improved analytical separation enabled to have cleaner UV and also MSⁿ measurements of the major photolytic degradation compounds. It was found that mostly isomers of **1** were formed.

5.3.4 Acetylcholinesterase (AChE) inhibition assay

The AChE inhibition assay was only performed with the degradation products formed under acidic conditions (**2**, **3** and **4**). The purity of the substances was determined to be at least 95% according to analysis with the analytical LC-UV (215 nm) system. Based on the methodology described in section 2.6, the IC₅₀ value observed for **1** was 1.03 μM, which is in good accordance with previously published values (0.5 - 1.4 μM) (Berkov *et al.*, 2008a, Bickel *et al.*, 1991). The IC₅₀ values for **2** and **4** were 425 and 692 μM, respectively. For substance **2**, this result was in good agreement with the literature (Thomson *et al.*, 1990). For substance **4**, no comparative data were found in the literature. Substance **3** did not show any activity against AChE. Overall, the isolated degradation products showed a lower bioactivity compared to **1** itself.




Figure 5.2 MS/MS spectra of non-deuterated galantamine (A), deuterated galantamine (B) and deuterated galantamine N-oxide (C). For details, refer to the text

Conclusions


A method to evaluate the stability of galantamine hydrobromide under different stress conditions was developed and validated, as indicated by ICH guidelines. Galantamine proved to be stable under alkaline conditions and at elevated temperatures. On the other hand, under acidic, oxidative and photolytic conditions significant degradation occurred. All formed degradation products were characterized chemically and biochemically as far as possible. Moreover, the degradation kinetics were also assessed and showed to follow first order kinetics for acidic and photolytic conditions. However, under oxidative conditions, a two phase kinetics behavior was observed, for which no valid explanation can be given. All tested degradation products of **1** showed very weak inhibitory activity against the target enzyme AChE.

Acknowledgements

We thank David Falck for his assistance concerning the IT-TOF measurements. L. Azevedo Marques was supported by the Alban programme, the European Union programme of high level scholarships for Latin America (scholarship E06D102010BR). The authors are also grateful for the kind supply of galantamine hydrobromide from Janssen Cilag (Tilburg, The Netherlands).

Supplementary material

S3 comment Table 2: the cited reference (Han *et al*, 1992) gives a singlet signal for two protons at 6.59 ppm, this seems to be a mistake in the original publication as these signals are found to be 2 doublets corresponding to the aromatic protons, which also has to be expected referring to the structure.



S2. UV spectra of the degradation compounds of galantamine hydrobromide formed under acidic, photolytic and oxidative conditions. Numbers corresponding to compounds as in Table 5.2.

S1. Summary of degradation compounds of galantamine hydrobromide formed under acidic, photolytic and oxidative conditions. The number corresponding to compounds as in Table 5.2, the corresponding *m/z* values of molecular ions and their fragments are shown. Moreover the probable molecular formulas with error margin in ppm are also shown. *m/z* values in bold means that MS3 experiments were performed.

Number	MS <i>m/z</i>	Most likely molecular formula	MS/MS <i>m/z</i>	Most likely Molecular formula
1	288.1593	$C_{17}H_{22}NO_3^+$	225.0905	$C_{15}H_{13}O_2^+$
			231.1018	$C_{14}H_{15}O_2^+$
			270.1484	$C_{17}H_{20}NO_2^+$
			213.0905	$C_{14}H_{13}O_2^+$
			197.0905	$C_{14}H_{13}O^+$
			209.0961	$C_{15}H_{13}O^+$
2	288.1593	$C_{17}H_{22}NO_3^+$	270.1481	$C_{17}H_{20}NO_2^+$
			209.0960	$C_{15}H_{13}O^+$
			213.0908	$C_{14}H_{13}O_2^+$
			181.1024	n.d.
			239.1062	$C_{16}H_{15}O_2^+$
3	270.1487	$C_{17}H_{20}NO_2^+$	239.1060	$C_{16}H_{15}O_2^+$
			179.0860	n.d.
			220.1121	$C_{16}H_{12}O^+$
4	270.1480	$C_{17}H_{20}NO_2^+$	209.0963	$C_{15}H_{13}O^+$
			181.1025	n.d.
			239.106	$C_{16}H_{15}O_2^+$

Error (ppm)	MS3 <i>m/z</i>	Most likely Molecular formula	Error (ppm)
-2.22			
0.87			
-1.85	255.12	C ₁₆ H ₁₇ NO ₂ ⁺⁺	3.5
	223.10	C ₁₅ H ₁₃ NO ₂ ⁺⁺	-8.8
	133.09	C ₉ H ₁₁ N ⁺⁺	-12.1
-2.35	198.06	C ₁₃ H ₁₀ O ₂ ⁺	0.66
	182.07	C ₁₃ H ₁₀ O ₂ ⁺	-7.6
-1.01			
0.00	181.10	C ₁₄ H ₁₃	-2.8
	166.08	n.d.	n.d.
	194.08	n.d.	n.d.
2.8	209.09	C ₁₅ H ₁₃ O ⁺	2.8
	255.13	C ₁₆ H ₁₇ NO ₂ ⁺⁺	1.1
	166.07	C ₁₁ H ₈ N ⁺⁺	-13.8
	189.09	C ₁₁ H ₈ O ⁺	4.3
	239.11	C ₁₆ H ₁₅ O ₂ ⁺	-2.3
0.44	181.10	n.d.	n.d.
	191.09	n.d.	n.d.
	166.08	n.d.	n.d.
0.97	198.07	C ₁₃ H ₁₀ O ₂ ⁺⁺	-1.9
	170.07	C ₁₂ H ₁₀ O ₂ ⁺	-13.5
n.d.			
1.92			
2.76	211.11	C ₁₅ H ₁₅ O ⁺	-1.7
	224.08	C ₁₅ H ₁₂ O ₂ ⁺	1.3
	179.09	n.d.	n.d.
n.d.	178.08	n.d.	n.d.
	152.06	n.d.	n.d.
10.35	193.10	n.d.	n.d.
	179.09	n.d.	n.d.
-1.0	181.10	n.d.	n.d.
	191.09	n.d.	n.d.
	166.08	n.d.	n.d.
n.d.	166.08	n.d.	n.d.
	153.07	n.d.	n.d.
1.5	224.08	n.d.	n.d.
	211.11	C ₁₅ H ₁₅ O ⁺	4.0
	179.08	n.d.	n.d.

Number	MS m/z	Most likely molecular formula	MS/MS m/z	Most likely Molecular formula
5	304.1551	$C_{17}H_{22}NO_4^+$	231.1012	$C_{14}H_{15}O_3^+$
	326.1111	Sodium adduct	213.0907	$C_{14}H_{13}O_2^+$
	213.0919	$C_{14}H_{13}O_2^+$	245.1165	$C_{15}H_{17}O_3^+$
			286.144	$C_{17}H_{20}NO_3^+$
6	306.1680	$C_{17}H_{24}NO_4^+$	231.1003	$C_{14}H_{15}O_3^+$
	286.1416	$C_{17}H_{20}NO_3^+$	288.1568	$C_{17}H_{20}NO_3^+$
			245.1162	$C_{15}H_{17}O_3^+$
			169.1046	$C_9H_{15}NO_2^+$
7	288.1573	$C_{17}H_{22}NO_3^+$	231.1005	$C_{14}H_{15}O_3^+$
			213.0895	$C_{14}H_{13}O_2^+$
			270.1474	$C_{17}H_{20}NO_2^+$
			203.1052	$C_{13}H_{15}O_2^+$
			245.1170	$C_{15}H_{17}O_3^+$
			163.0750	$C_{10}H_{11}NO_2^+$
			112.0758	$C_6H_{10}NO_2^+$
			288.1571	$C_{17}H_{22}NO_3^+$
			231.0992	$C_{14}H_{15}O_3^+$
			225.0890	$C_{15}H_{13}O_2^+$
270.1471	$C_{17}H_{20}NO_2^+$			
8	306.1680	$C_{17}H_{24}NO_4^+$	213.0886	$C_{14}H_{13}O_2^+$
	288.1578	$C_{17}H_{22}NO_3^+$	197.0950	$C_{14}H_{13}O_2^+$
9	288.1572	$C_{17}H_{22}NO_3^+$	231.1001	$C_{14}H_{15}O_3^+$
			203.1050	$C_{13}H_{15}O_2^+$
2	288.1577	$C_{17}H_{22}NO_3^+$	270.1477	$C_{17}H_{20}NO_2^+$
			209.0945	$C_{15}H_{13}O^+$
			213.0894	$C_{14}H_{13}O_2^+$
10	288.1577	$C_{17}H_{22}NO_3^+$	231.1019	$C_{14}H_{15}O_3^+$
			270.1477	$C_{17}H_{20}NO_2^+$
			213.0891	$C_{14}H_{13}O_2^+$
			133.0884	$C_9H_{11}N^+$
			218.1154	$C_{13}H_{16}NO_2^+$
			270.1478	$C_{17}H_{20}NO_2^+$
			232.1330	$C_{14}H_{18}NO_2^+$
203.1049	$C_{13}H_{15}O_2^+$			
11	288.1571	$C_{17}H_{22}NO_3^+$	227.1057	$C_{15}H_{15}O_2^+$
			175.0752	$C_{11}H_{11}O_2^+$

Error (ppm)	MS3 <i>m/z</i>	Most likely Molecular formula	Error (ppm)
1.6	213.09	$C_{14}H_{13}O_2^+$	5.2
1.4	198.07	$C_{13}H_{10}O_2^{+•}$	-2.9
2.9	213.09	$C_{14}H_{13}O_2^+$	8.9
	203.11	$C_{14}H_{13}O_2^+$	-6.7
	217.12	$C_{14}H_{17}O_2^+$	-7.4
1.2	209.09	$C_{15}H_{13}O^+$	6.2
5.6			
9.0	n.d.	n.d.	n.d.
4.1			
0.6			
4.8			
7.0			
5.5	254.12	$C_{16}H_{16}NO_2^+$	8.7
7.4			
0.8			
2.5			
0.9			
7.9			
	225.09	$C_{15}H_{13}O_2^+$	8.4
10.3	231.10	$C_{14}H_{15}O_3^+$	6.9
8.9	270.15	$C_{17}H_{20}NO_2^+$	4.4
6.7			
	255.12	$C_{16}H_{17}NO_2^{+•}$	8.6
11.3	133.09	$C_9H_{11}N^{+•}$	5.5
5.6	223.10	n.d.	n.d.
6.5			
8.4	n.d.	n.d.	n.d.
4.4			
7.7			
7.5		n.d.	
1.3	209.09		n.d.
4.4	213.09	$C_{14}H_{13}O_2^+$	9.4
8.9	133.09	$C_9H_{11}N^{+•}$	5.3
1.6			
10.1			
4.1		n.d.	
0.9	239.10	$C_{12}H_{13}O_2^+$	n.d.
8.9	189.09	$C_{15}H_{15}O_2^+$	7.9
4.4	227.11	n.d.	5.3
1.1	215.09		n.d.

References

- Bakshi M and Singh S. *Development of validated stability-indicating assay methods--critical review*. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 1011-1040.
- Berkov S, Bastida J, Nikolova M, Viladomat F and Codia C. *Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts* Phytochemical Analysis 2008a; 19: 411-419.
- Berkov S, Codina C, Viladomat F and Bastida J. *N-alkylated galanthamine derivatives: Potent acetylcholinesterases inhibitors from *Leucocjum aestivum**. Bioorganic and Medicinal Chemistry Letters 2008b; 18: 2263-2266.
- Bickel U, Thomsen T, Fischer JP, Weber W and Kewitz H. *Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice* Neuropharmacology 1991; 30: 447-454.
- The United States Pharmacopoeial Convention, *Official Monograph galantamine*, Revision Bulletin 15 december 2008.
- de Jong CF, Derks RJ, Bruyneel B, Niessen W and Irth H. *High-performance liquid chromatography-mass spectrometry-based acetylcholinesterase assay for the screening of inhibitors in natural extracts*. Journal of Chromatography A 2006; 1112: 303-310.
- European Pharmacopoeial 7th edition, *Monography Galantamine hydrobromide*. 2010a: Strasbourg, France.
- European Pharmacopoeial 7th edition. *Monography Hydrogen peroxide solution (3 per cent)*. 2010b: Strasbourg, France.
- Han SY, Sweeney JE, Bachman ES, Schweiger EJ, Forloni G, Coyle JT, Davis BM and Joullié MM. *Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease?* European Journal of Medicinal Chemistry 1992; 27: 673-687.
- Hoffmann M and Hock C. *Alzheimer's disease: Antidementive Drugs*. International Encyclopedia of the Social & Behavioral Sciences 2004: 418-423.
- ICH. (Q2R1) *Validation of Analytical Procedures: Text and Methodology*, International Conference on Harmonisation, Geneva November 2005.
- Jegorov A, Buchta M, Sedmera P, Kuzma M and V. Havlicek. *Accurate product ion mass spectra of galanthamine derivatives* Journal of Mass Spectrometry 2006; 41: 544-548.
- Küenburg B, Czöllner L, Fröhlich J and Jordis U. *Development of a pilot scale process for the anti-alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallization-induced chiral conversion*. Organic Process Research and Development 1999; 3: 425-431.
- Kumar S, Rurak DW and Riggs KW. *Simultaneous determination of diphenhydramine, its N-oxide metabolite and their deuterium-labeled analogues in ovine plasma and urine using liquid chromatography/electrospray tandem mass spectrometry*. Journal of Mass Spectrometry 1998; 33: 1171-1181.
- Lee TBK, Goehring KE and Ma Z. *One-step conversion of galanthamine to lycoraminone: A novel hydride-transfer reaction*, Journal of Organic Chemistry Chem. 63 (1998) 4535-4538.
- Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC and Costantino HR. *Development of a novel high-concentration galantamine formulation suitable for intranasal delivery*. Journal of Pharmaceutical Sciences 2005; 94: 1736-1746.
- Liu DQ, Hop CECA. *Strategies for characterization of drug metabolites using liquid-chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches*. Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 1-18.
- Lubbe A, Pomahacová B, Choi YH and Verpoorte R. *Analysis of metabolic variation and galanthamine content in *Narcissus bulbs* by ¹H NMR* Phytochemical Analysis 2010; 21: 66-72.
- Malakova J, Nobilis M, Svoboda Z, Lisa M, Holcapek M, Kvetina J, Klimes J and Palicka V. *High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples*. Journal of Chromatography B 2007; 853: 265-274.
- Marques LA, Giera M, de Kanter FJJ, Niessen WMA, Lingeman H and Irth H. *Photohuperzine A-A new photoisomer of huperzine A: Structure elucidation, formation kinetics and activity assessment*. Journal of Pharmaceutical and Biomedical Analysis 2010a; 52: 190-194.
- Marques LA, Kool J, de Kanter F, Lingeman H, Niessen W and Irth H. *Production and on-line acetylcholinesterase bioactivity profiling of chemical and biological degradation products of tacrine*. Journal of Pharmaceutical and Biomedical Analysis 2010b; 53: 609-616.
- Visky D, Jimidar I, Van Ael W, Vennekens T, Redlich D and De Smet M. *Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products*. Electrophoresis 2005; 26: 1541-1549.
- Zhang LH, Gupta AK and Cook JM. *Reinvestigation of the mechanism of the acid-catalyzed epimerization of reserpine to isoreserpine*. Journal of Organic Chemistry 1989; 54: 4708-4712.